Chf-5074 clinical trials
Also written CHF 5074.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses chf-5074 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
CERESPIR (5) · Chiesi Farmaceutici S.p.A. (2)
Often tested with
Tested in the same studies.
CHF 5974 (1)
Studies
Open first, then newest update. How each study uses chf-5074 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074CompletedPhase 2CERESPIRNCT01303744Written as CHF 5074 1x
- Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male SubjectsCompletedPhase 1CERESPIRNCT01203384Written as CHF5074 1x
- Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male SubjectsCompletedPhase 1CERESPIRNCT01258452Written as CHF 5074
- Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male SubjectsCompletedPhase 1CERESPIRNCT00954252Written as CHF 5074
- Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive ImpairmentWithdrawnPhase 2CERESPIRNCT01723670Written as CHF 5074 1x
- Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)CompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01421056Written as CHF 5074 1x
- Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension PhaseCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT01602393Written as CHF 5074 1x